Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnologies Inc (NQ: ADVM )

6.880 +0.020 (+0.29%)
Streaming Delayed Price Updated: 1:58 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adverum Biotechnologies Inc

< Previous 1 2 3 4 Next >
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
ISS Recommends Adverum Stockholders Vote to Elect Sonic’s Three Independent, Highly Qualified Nominees
From The Sonic Fund II, L.P.
Via Business Wire
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) rose 58.3% to $78.90 in pre-market trading. Nicholas Jason Singer disclosed a 9.13% passive stake in Brooklyn... 
Via Benzinga
Adverum's Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced Patients
Adverum Biotechnologies Inc (NASDAQ: ADVM) has announced new long-term data from the OPTIC Phase 1 trial of ADVM-022 single intravitreal (IVT) injection gene... 
Via Benzinga
Why Adverum Biotechnologies Stock Is Plummeting Today
Adverum Biotechnologies (NASDAQ: ADVM) shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical... 
Via Benzinga
The Sonic Fund II, L.P. Comments on Adverum Biotechnologies Update Regarding INFINITY Phase 2 Trial of ADVM-022
From The Sonic Fund II, L.P.
Via Business Wire
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Mid-Afternoon Market Update: Dow Gains 175 Points; JAKKS Pacific Shares Climb After Q1 Results
Toward the end of trading Thursday, the Dow traded up 0.52% to 33,995.76 while the NASDAQ rose 0.13% to 14,069.67. The S&P also rose, gaining 0.50% to 4,204.22. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock rose 21.78% to $8.05 during Thursday's regular session. As of 12:32 EST, Galera Therapeutics's stock is trading at... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs. Takung Art Co., Ltd. (... 
Via Benzinga
Mid-Day Market Update: Nasdaq Turns Lower; Galera Therapeutics Shares Surge
Midway through trading Thursday, the Dow traded up 0.14% to 33,868.84 while the NASDAQ fell 0.33% to 14,004.20. The S&P also rose, gaining 0.15% to 4,189.46. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
54 Stocks Moving In Thursday's Mid-Day Session
Gainers Willamette Valley Vineyards, Inc. (NASDAQ: WVVI) climbed 40.5% to $14.39. Dolphin Entertainment, Inc. (NASDAQ: DLPN) shares gained 23.1% to $14.14. Dolphin Entertainment... 
Via Benzinga
Why Adverum Biotechnologies Stock Is Imploding Today
Investors are running for the hills following the company's latest clinical update. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2021
Upgrades According to Vertical Research, the prior rating for Entergy Corp (NYSE:ETR) was changed from Hold to Buy. For the first quarter, Entergy had an EPS of $1.47,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 5 companies set new 52-week lows. Noteables: Lufax Holding (NYSE:LU) was the largest firm on a market cap basis to set a new... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; McDonald's Profit Beats Estimates
Following the market opening Thursday, the Dow traded up 0.23% to 33,899.83 while the NASDAQ rose 0.25% to 14,086.11. The S&P also rose, gaining 0.49% to 4,203.60. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) shares increased by 42.2% to $9.4 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 39.6% to $9.23 in pre-market trading after the company disclosed updated data from its randomized, multicenter, placebo-... 
Via Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
Adverum's Stock Crashes After DME Gene Therapy Trial Derails On One Patient's Serious Adverse Event
Adverum Biotechnologies Inc (NASDAQ: ADVM) stock has cratered in reaction to a Suspected Unexpected Serious Adverse Reaction of hypotony (clinically-relevant decrease... 
Via Benzinga
The Sonic Fund II, L.P. Issues Presentation Correcting Adverum’s Misstatements
From The Sonic Fund II, L.P.
Via Business Wire
The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.
From The Sonic Fund II, L.P.
Via Business Wire
The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc.
From The Sonic Fund II, L.P.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 62 stocks made new 52-week lows. Significant Points: The largest company by market cap to set a new 52-week low was Yatsen Holding (NYSE:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows. Interesting Highlights: The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (... 
Via Benzinga
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS